Martin Shkreli

Investors should consider Cullinan Therapeutics (CGEM) as a value opportunity, as the stock currently trades around $15 despite sophisticated institutional investors recently paying $19 per share. In the semiconductor space, Micron (MU) and SK Hynix remain high-conviction plays driven by intense AI demand and strong sector momentum. While Amgen (AMGN) is an "execution machine" with massive revenue from Repatha and Crystexa, investors should remain cautious and monitor upcoming data for their weight loss drug, MariTide. Vaxcyte (PCVX) offers high-reward potential and could "certainly double" if its pneumococcal vaccine successfully competes with Pfizer, though it remains a high-risk biotech play. For long-term growth in the weight loss sector, keep a close eye on Viking Therapeutics (VKTX) and its lead candidate VK2735, though full commercialization is not expected until 2027.

Spruce Biosciences (SPRB) is a high-conviction "10x" opportunity with a personal price target of $500, driven by a potential $100 million Priority Review Voucher sale and a strategic BLA filing delay to Q4. Sarepta Therapeutics (SRPT) offers a strong value play with a "valuation floor," as its market cap sits near annual revenue and its gene therapy pipeline could reach $3B in sales. Investors should consider shorting IonQ (IONQ), which is described as a "house of cards" with inorganic revenue growth and a lack of essential quantum technology. Avoid Super Micro Computer (SMCI) due to high-risk smuggling allegations and Bristol Myers Squibb (BMY) as it faces a massive patent cliff for Eliquis and a heavy debt load. For long-term exposure to the successor of GPUs, look toward Optical Computing players like Lumentum (LITE), Coherent (COHR), and Fabrinet (FN).

NVIDIA (NVDA) is a primary investment opportunity as its growth is accelerating, with next-quarter revenue guidance of $78 billion massively beating expectations. The core thesis is to invest in the AI infrastructure theme, as the exponential demand for computing power represents a new industrial revolution. As a key semiconductor supplier, Micron (MU) is also positioned to benefit significantly from the sustained capital spending in the AI sector. Conversely, investors should avoid quantum computing company IonQ (IONQ) due to strong concerns about its revenue quality and fundamentals. For accredited investors, the bonds of private AI cloud provider Core Weave offer a high-yield opportunity, with its 2030 bonds yielding around 8%.

A high-conviction sell recommendation was issued for SELLAS Life Sciences (SLS), with the analyst stating the company's drug "does not work" and urging investors to exit the position immediately. Investors are advised to avoid quantum computing stocks like IonQ (IONQ) and D-Wave (QBTS) for AI applications, as the technology is considered a "dead end" for these workloads. A bearish sentiment was expressed for Viking Therapeutics (VKTX), with the analyst suggesting its positive run is likely over. Despite strong fundamentals, Eli Lilly (LLY) may have limited near-term upside from its $1,000 price, with valuation models suggesting a target of around $1,100. The key long-term theme is identifying the successor to NVIDIA (NVDA), with photonic computing seen as a more promising field than quantum.